On November 29, 2022, the Company was formed with an initial issuance of 12,258,458 shares of stock at € .01 par value for a total of € 122,585.

During 2023, the Company completed the February 2023 common-control transaction pursuant to which intellectual property was transferred from Davion Healthcare Limited (United Kingdom) to the Company. In connection with the overall transaction, the Company’s issued share capital was reorganised such that 12,258,458 ordinary shares were held by the relevant shareholders and an additional 7,741,542 ordinary shares were issued at €0.01 par value, resulting in 20,000,000 ordinary shares in issue. The intellectual property transferred in the transaction has been recognised separately at its predecessor carrying amount, as described in Note 7.

During the year ended 2024, the Company issued 4,401,800 shares of stock to various creditors and shareholders in exchange of amounts due to them of €919,663 and issued 598,246 shares of stock to its officers in exchange for amounts due to them of €5,600,000.

The Company is not subject to any externally imposed capital requirements.